focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOvoca Bio Share News (OVB)

Share Price Information for Ovoca Bio (OVB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.825
Bid: 0.75
Ask: 0.90
Change: 0.00 (0.00%)
Spread: 0.15 (20.00%)
Open: 0.825
High: 0.825
Low: 0.825
Prev. Close: 0.825
OVB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS: Ovoca "to adapt" after study let-down, Kelso NAV rises

Thu, 28th Sep 2023 14:41

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Marwyn Value Investors Ltd - St Helier, Jersey-headquartered closed-ended investment company with investments including AdvancedAdvT Ltd, 450 PLC and Zegona Communications PLC - Net asset value per share at June 30 was 167.55 pence, down from 176.81p at the same time one year prior. Reports total NAV return of negative 2.7% for the first half of 2023, underperforming against the FTSE All-Share benchmark index which delivered positive 2.6%. Declares 4.53p per share half-year dividend, expects total annual dividend of 9.06p. Company notes "prevalent speculation and a somewhat unrealistic expectation regarding a return to ultra-low interest rates." Chair Robert Ware says portfolio "is exceptionally poised to capitalise on forthcoming opportunities, and we eagerly anticipate witnessing the growth and evolution of our portfolio companies."

----------

Fintech Asia Ltd - investment firm established to acquire Asian financial services companies - Pretax loss for year ended June 30 was GBP1.3 million, widened from a GBP397,971 loss in financial 2022. Notes change of financial year end, announced in late June, from June 30 to December 31. Says it has continued to advance discussions regarding reverse takeover of InvesCore Financial Group Pte Ltd following head of terms agreement in March. Hopes to agree terms to conclude a definitive acquisition agreement and seek regulatory approval for its shares, suspended in mid-March, to be readmitted to the Main Market. Confirms that "the process remains active and ongoing" but cannot confirm that the above will be successful.

----------

DG Innovate PLC - Bradford, England-based electric mobility and energy storage company - Pretax loss for first half of 2023 was GBP1.9 million, reduced from GBP6.5 million the year before. Revenue increased to GBP30,240 from no revenue, while grant income increased to GBP399,641 from GBP344,831. Cash at June 30 was GBP159,958, down from GBP1.7 million at the same time in 2022. Total administrative expenses (including share-based payments) increased 33% to GBP2.3 million from GBP1.7 million. Incurred zero reverse acquisition expenses, down from GBP5.1 million. Says testing of its Pareta high-performance electric vehicle drive is ongoing; plans to move into pilot manufacturing and volume supply "in due course."

----------

Ovoca Bio PLC - Dublin-based, women's health-focused biopharmaceutical company - Reports EUR2.4 million pretax loss for the first half of 2023, narrowed from EUR5.6 million the prior year. Administrative expenses fell to EUR1.0 million from EUR3.0 million. Says its focus remains on developing Orenetide, but says it "will need to adapt its approach" following "disappointing" phase 2 study results announced on August 31. The study found that Orenetide did not show statistically significant superiority compared with a placebo in treating a lack or loss of sexual desire in female test subjects. Ovoca says near-term efforts will be directed towards reviewing "the current situation" and assessing all current opportunities.

----------

Kelso Group Holdings PLC - London-headquartered investor backing small and mid-cap UK companies - NAV at June 30 was 2.2p per share, up from 1.1p on the same day in 2022. Pretax profit for the six months ended June 30 was GBP1.3 million, up from GBP56,960 the year before. Revenue increased from nothing to GBP1.8 million. Says medium-term aim is to grow its investment business, which is prepared to work actively with portfolio companies. Portfolio currently consists of THG PLC and TheWorks.co.uk PLC; it announced its purchase of 2.0 million TheWorks shares for 31.3p each on Monday. Says it is building its third investment and aims to start investing in a further company shortly, and says that value opportunities "remain plentiful."

----------

Landore Resources Ltd - Ontario, Canada-focused precious and base metal project explorer and developer - Pretax loss for the first half of 2023 was GBP822,251, widened from GBP794,385 last year. Operating loss was virtually unchanged at GBP1.2 million. Cash and equivalents at June 30 totalled GBP397,109, down from GBP1.2 million at December 31. Exploration costs decreased 39% to GBP242,502 from GBP398,341. Says preparatory work is currently underway to follow up on promising drill and soil test results at BAM gold project, which it will focus on advancing throughout the remainder of 2023.

----------

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
2 Oct 2020 10:54

Russian Health Ministry Rejects Ovoca Bio's BP-101 Application

Russian Health Ministry Rejects Ovoca Bio's BP-101 Application

Read more
2 Oct 2020 10:10

Ovoca Bio hits stumbling block in Russia drug approval

(Sharecast News) - Biopharmaceutical company Ovoca Bio updated shareholders on Friday on its marketing authorisation application for BP-101, a novel synthetic peptide administered through a nasal spray, that was submitted to the Russian Ministry of Health (Minzdrav) in September 2019.

Read more
28 Sep 2020 15:53

UK EXECUTIVE CHANGE SUMMARY: Tracsis Appoints New Finance Chief

UK EXECUTIVE CHANGE SUMMARY: Tracsis Appoints New Finance Chief

Read more
21 Sep 2020 21:19

IN BRIEF: Ovoca Bio Pretax Loss Widens In First Half Of 2020

IN BRIEF: Ovoca Bio Pretax Loss Widens In First Half Of 2020

Read more
26 Jun 2020 11:58

Ovoca Bio Annual Loss Slightly Narrows; Capital Base "Strong"

Ovoca Bio Annual Loss Slightly Narrows; Capital Base "Strong"

Read more
24 Mar 2020 18:39

Ovoca Bio Completes Buyout Of Russia's IVIX For USD5 Million

Ovoca Bio Completes Buyout Of Russia's IVIX For USD5 Million

Read more
16 Sep 2019 11:33

Ovoca Bio narrows losses as BP-101 trials continue

(Sharecast News) - Biopharmaceutical firm Ovoca Bio narrowed losses slightly in the first half of its trading year, while focus remained firmly on its continued development of a treatment for female sexual dysfunction.

Read more
16 Sep 2019 10:48

Ovoca Bio Interim Loss Widens On Administration Expenses

(Alliance News) - Ovoca Bio PLC on Monday said its loss widened in the first half of the year, suffering higher administration expenses in the year as it worked to develop its BP-101 female sexual

Read more
28 Aug 2019 14:43

Ovoca Bio Non-Executive Nikolay Myasoyedov Leaves For Personal Reasons

(Alliance News) - Ovoca Bio PLC on Wednesday said Non-Executive Director Nikolay Myasoyedov intends to step down from the board with immediate effect for personal reasons.The pharmaceutical

Read more
8 Aug 2019 11:24

Ovoca Bio's Libicore Application Result Expected A Year After Filing

(Alliance News) - Ovoca Bio PLC on Thursday said it intends to file for the approval of its Libicore female sexual dysfunction drug later in the quarter and expects the verdict in a year's 16%

Read more
26 Jul 2019 17:03

Ovoca Bio Says Non-Executive Director Yuri Radchenko Has Left Role

(Alliance News) - Drug company Ovoca Bio PLC said on Friday Yuri Radchenko, a non-executive director, has stepped down with immediate effect due to personal reasons.Chief Executive Kirill I

Read more
28 Jun 2019 15:07

Ovoca Bio Loss Widens; Prepares For Market Approval Filing For Libicore

(Alliance News) - Ovoca Bio PLC on Friday said its annual loss widened heavily as a result of administration expenses and said it is preparing to file for marketing approval of its drug BP101 in a

Read more
23 Apr 2019 15:40

Ovoca Bio's IVIX ropes in Biorasi for development of 'Libicore' drug candidate

(Sharecast News) - Ovoca Bio announced on Tuesday that its subsidiary IVIX has begun the process of preparing an integrated clinical development plan for its investigational drug candidate, 'Libicore' (BP-101), for both the US and EU regions with US-based contract research organisation Biorasi.

Read more
27 Mar 2019 10:21

Ovoca Bio Expands IVIX Stake Amid Strong Libicore Drug Trial Results

LONDON (Alliance News) - Ovoca Bio PLC said Wednesday it increased its stake in a majority-owned subsidiary following a positive set of test results from its Libicore sexual desire - known as Gold

Read more
25 Mar 2019 12:13

Ovoca Bio To Seek Russian Approval For Libicore After Successful Trial

LONDON (Alliance News) - Ovoca Bio PLC on Monday said it intends to file for the approval of its hypoactive sexual desire disorder drug Libicore in Russia after positive results from a recent in a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.